C7744
溴他汀 A4
≥98% (HPLC), vascular disrupting agent, powder
别名:
1-（3,4,5-三甲氧基苯基）-2-（3′-羟基-4′-甲氧基苯基）乙烷 3,4,5-三甲氧基-3′-羟基-4′--甲氧基芪, 2-甲氧基-5-[(1Z)-2-（3,4,5-三甲氧基苯基）乙烯基] 苯酚, CA4
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H20O5
化学文摘社编号:
分子量:
316.35
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
溴他汀 A4, ≥98% (HPLC), powder
SMILES string
COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O
InChI key
HVXBOLULGPECHP-WAYWQWQTSA-N
InChI
1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-
assay
≥98% (HPLC)
form
powder
color
off-white
solubility
DMSO: >10 mg/mL
storage temp.
−20°C
Quality Level
General description
考布他汀A4属于秋水仙碱类。
Application
考布他汀A4已被用于：
- 作为抗微管剂用于确定G2/M期异柠檬酸脱氢酶（IDH1和IDH2）蛋白的作用
- 评估联苯CA4衍生物在2D和3D癌细胞和非癌细胞模型中的的抗增生和促凋亡特性
- 作为微管抑制剂用于研究其对猪蛔虫L3幼虫的作用
Biochem/physiol Actions
Combretastatin A4是一种靶向肿瘤血管以抑制血管生成的血管分裂剂(VDA)。
Combretastatin A4是一种靶向肿瘤血管以抑制血管生成的血管分裂剂(VDA)。它在β-微管蛋白的秋水仙碱结合位点抑制微管蛋白聚合。它通过抑制人胃细胞中的AKT功能而具有抗肿瘤活性。被抑制的 AKT 激活引起细胞增殖下降，细胞周期停滞，在体外 迁移/侵袭和 体内 转移能力降低 。Combretastatin A4 是一种天然二苯乙烯类苯酚。
考布他汀A4是一种强效的微管靶向剂。
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Eye Dam. 1
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Christian Damsgaard et al.
eLife, 9 (2020-08-26)
Previously, we showed that the evolution of high acuity vision in fishes was directly associated with their unique pH-sensitive hemoglobins that allow O2 to be delivered to the retina at PO2s more than ten-fold that of arterial blood (Damsgaard et
De novo identification of toxicants that cause irreparable damage to parasitic nematode intestinal cells
Jasmer DP, et al.
PLoS Neglected Tropical Diseases, 14(5), e0007942-e0007942 (2020)
Abundance of d-2-hydroxyglutarate in G2/M is determined by FOXM1 in mutant IDH1-expressing cells
Bala Bhaskara Rao K, et al.
Febs Letters, 593(16), 2177-2193 (2019)
Medicinal chemistry of combretastatin A4: present and future directions.
Gian Cesare Tron et al.
Journal of medicinal chemistry, 49(11), 3033-3044 (2006-05-26)
Thomas Nielsen et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 18(23), 6469-6477 (2012-10-17)
Combretastatin A-4 disodium phosphate (CA4P) is a promising vascular disrupting agent (VDA) in clinical trials. As CA4P acts on dividing endothelial cells, we hypothesize that CA4P affects vessels of certain sizes. The aim of this study was to evaluate the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持